Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
{arrow_up} Back to top

Colazide 750mg Capsules

Active Ingredient:
balsalazide disodium
Almirall Limited See contact details
ATC code: 
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 03 Jan 2019
1. Name of the medicinal product

Colazide 750 mg hard capsules

2. Qualitative and quantitative composition

Each capsule contains 750 mg of balsalazide disodium corresponding to balsalazide 612.8 mg and to mesalazine 262.5 mg.

For the full list of excipients, see section 6.1.

3. Pharmaceutical form

Capsule, hard.

Size 00 beige gelatin capsules.

4. Clinical particulars
4.1 Therapeutic indications

Colazide is indicated for the treatment of mild-to-moderate active ulcerative colitis and maintenance of remission.

4.2 Posology and method of administration



Treatment of active disease:

2.25g Balsalazide disodium (3 capsules) three times daily (6.75g daily) until remission or for 12 weeks maximum.

Rectal or oral steroids can be given concomitantly if necessary.

Maintenance treatment:

The recommended starting dose is 1.5g Balsalazide disodium (2 capsules) twice daily (3g daily). The dose can be adjusted based on each patient's response; there may be an additional benefit with a dose up to 6g daily.


No dose adjustment is anticipated.

Paediatric Population:

Colazide is not recommended in children.

Method of administration

To be swallowed whole with or after food.

4.3 Contraindications

Hypersensitivity to the active substance, to its metabolites, including mesalazine, or to any of the excipients listed in section 6.1.

History of hypersensitivity to salicylates.

Severe hepatic impairment, moderate-severe renal impairment.

Pregnant and breast feeding women.

4.4 Special warnings and precautions for use

Colazide should be used with caution in patients with asthma, bleeding disorders, active ulcer disease, mild renal impairment or those with established hepatic disease.

Renal function should be monitored before starting an oral aminosalicylate, at 3 months of treatment, and then annually during treatment (more frequently in renal impairment). Blood disorders can occur with aminosalicylates (see recommendation below).

Blood disorders

During treatment with Colazide blood counts, BUN/creatinine and urine analysis should be performed. Patients receiving aminosalicylates should be advised to report any unexplained bleeding, bruising, purpura, sore throat, fever or malaise that occurs during treatment. A blood count should be performed and the drug stopped immediately if there is suspicion of a blood dyscrasia.

4.5 Interaction with other medicinal products and other forms of interaction

Formal interaction studies have not been performed with Colazide. Available data suggest that the systemically available amounts of balsalazide and its metabolites may be increased if Colazide is administered in the fasting as compared with the fed state. Therefore, Colazide should preferably be administered with food.

The acetylated metabolites of balsalazide are actively secreted in the renal tubule to a high degree. Therefore, plasma levels of co-prescribed drugs also eliminated by this route may be raised and this should be noted in the case of those with a narrow therapeutic range, such as methotrexate.

Pharmacodynamic interactions have not been studied. However, while balsalazide, mesalazine, and N-acetylmesalazine are salicylates chemically, their properties and kinetics make classical salicylate interactions such as those found with acetylsalicylic acid very unlikely.

The uptake of digoxin has been impaired in some individuals by concomitant treatment with sulphasalazine. Even if it is not known whether this would occur also during treatment with balsalazide, it is recommended that plasma levels of digoxin should be monitored in digitalised patients starting Colazide.

Mesalazine inhibits thiopurine methyltransferase. In patients receiving azathioprine or 6-mercaptopurine, caution is recommended for concurrent use of mesalazine as this can increase the potential for blood dyscrasias.

4.6 Fertility, pregnancy and lactation


Human experience with balsalazide is limited, therefore Colazide should not be given to pregnant women.


Colazide should not be given to breast feeding women as the active metabolite mesalazine has produced adverse effects in nursing infants.


Animal studies on fertility and reproductive function did not reveal adverse effects of balsalazide.

4.7 Effects on ability to drive and use machines

Colazide has no or negligible influence on the ability to drive and use machines.

4.8 Undesirable effects

The adverse effects are expected to be those of mesalazine.

Reactions reported during treatment with oral mesalazine are listed in the table below.

Organ group

Adverse Event

Blood and lymphatic system disorders

Blood dyscrasias

Aplastic anaemia Leucopenia

Neutropenia Agranulocytosis


Nervous system disorders



Cardiac disorders



Respiratory, thoracic and mediastinal disorders


Allergic alveolitis

Eosinophilic pneumonia

Gastrointestinal disorders

Abdominal pain


Nausea, vomiting

Aggravation of ulcerative colitis

Acute pancreatitis

Hepatobiliary disorders



Skin and subcutaneous tissue disorders




Musculoskeletal and connective tissue disorders

Systemic lupus erythematosus-like syndrome



Renal and urinary disorders

Interstitial nephritis

Acute renal failure

Renal insufficiency

Renal impairment

Immune system disorders


See Section 4.4 Special warnings and precautions for use.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme, Website: or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

To date, there are no reports of overdosage with mesalazine-releasing products. Overdose with large amounts of balsalazide may result in symptoms resembling mild salicylate intoxication. Treatment should be symptomatic.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Aminosalicylic and similar agents, ATC code: A07EC.

Balsalazide consists of mesalazine linked to a carrier molecule (4-aminobenzoyl-ß -alanine) via an azo bond.

Bacterial azo-reduction releases mesalazine as an active metabolite in the colon. Mesalazine is an intestinal anti-inflammatory agent acting locally on the colonic mucosa. Its precise mechanism of action is unknown. Balsalazide and the carrier do not contribute to the pharmacodynamic action.

5.2 Pharmacokinetic properties

The pharmacokinetics of balsalazide and its metabolites have been studied in healthy subjects and patients in remission. The systemic uptake of balsalazide itself is low (<1%) and the major part of the dose is split in the colon by bacterial azoreductase. This cleavage results in the primary metabolites 5-aminosalicylic acid (5-ASA), responsible for the anti-inflammatory action, and 4-aminobenzoyl-beta-alanine (4-ABA), considered to be an inert carrier.

Most of the dose is eliminated via the faeces but about 25% of the released 5-ASA appears systemically predominantly as the N-acetylated metabolite (NASA) after inactivation in the colonic mucosa and liver. The systemic uptake of 4-ABA is only 10-15% of that of 5-ASA and also this metabolite is grossly N-acetylated (to NABA) in the first pass.

In urine, virtually only NASA and NABA are recovered and their renal clearances are high: 0.2-0.3 L/min and 0.4-0.5 L/min, respectively. The half-life of NASA is in the order of 6-9 hours. The half-life of 5-ASA itself is very short: about 1 hour.

Because of the great importance of renal clearance for the elimination, Colazide should be used with caution in renal impairment. No studies have been performed in patients with hepatic disease.

Protein binding of 5-ASA is about 40% and that of NASA about 80%. Available data suggest that the pharmacokinetics of balsalazide is not affected by genetic polymorphism, nor does age seem to be an important factor. Fasting slightly increases the systemic uptake of balsalazide and its metabolites.

5.3 Preclinical safety data

Preclinical data reveal no special hazard for humans based on conventional studies of genotoxicity, carcinogenic potential, toxicity to reproduction, safety pharmacology and validating kinetics and metabolism. In repeated dose toxicity studies, nephrotoxicity, an effect known to occur following mesalazine, was observed particularly in rats.

6. Pharmaceutical particulars
6.1 List of excipients

Magnesium stearate, colloidal anhydrous silica, gelatin, shellac, titanium dioxide (E 171), yellow, red and black iron oxide (E 172).

6.2 Incompatibilities

Not applicable

6.3 Shelf life

3 years.

6.4 Special precautions for storage

No special precautions for storage.

6.5 Nature and contents of container

High density polyethylene container fitted with tamper-evident, child-resistant, high density polyethylene screw caps.

Pack sizes are: 50, 54, 56, 100, 112, 130, 224 (2 x 112), 260 (2 x 130), 300 (3 x 100), 500 (10 x 50), 672 (6 x 112) and 780 (6 x 130) capsules.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling


7. Marketing authorisation holder

Almirall, S.A.

Ronda General Mitre, 151

08022 Barcelona


8. Marketing authorisation number(s)

PL 16973/0019

9. Date of first authorisation/renewal of the authorisation

Date of first authorisation: 18 December 1997

Date of latest renewal: 11 August 2009

10. Date of revision of the text

17 September 2018

Almirall Limited
Company image
Almirall Limited, Harman House, 1 George Street, Uxbridge, Middlesex, UB8 1QQ, UK
+44 (0) 207 160 2500
Medical Information Direct Line
0800 0087399
Medical Information e-mail
[email protected]
Stock Availability
0800 0087399